http://web.archive.org/web/20150711052844id_/http://www.dailymail.co.uk/news/article-2890616/Patients-won-t-vital-pancreatic-cancer-drug-extend-life-NHS.html

the first breakthrough drug for pancreatic cancer in 20 years will not be available on the @entity2			1
hundreds of patients with advanced disease will be denied @entity5 , which extends life by two months when there are virtually no other options			1
campaigners said draft guidance by @entity12 ( the @entity12 ) , the rationing watchdog for @entity14 , that the drug was not cost effective would leave patients in despair			1
hundreds of patients with advanced forms of pancreatic cancer will be denied @entity5 , which extends life by two months when there are virtually no other options , after it was decided the drug is not cost effective @entity26 , founder and ceo of the charity @entity28 , said ‘ we are outraged by the decision			1
‘ this is the first time @entity12 has looked at an effective treatment for the disease since 2001 and they have rejected it			0
‘ there is a real disparity between survival rates here , which have been unchanged for 40 years , and elsewhere in @entity37 where patients survive twice as long and this decision is a backward step			2
’ about 8,500 @entity41 are diagnosed annually with pancreatic cancer , which kills four in five sufferers within a year			2
tumours are hard to detect because the pancreas is buried deep in the body so symptoms emerge when the disease is at an advanced stage			0
pancreatic cancer claimed the lives of @entity53 co-founder @entity52 and author @entity54 , and was the disease which triggered the character @entity56 in tv ’s @entity57 to kill herself			1
pancreatic cancer claimed the lives of @entity53 co-founder @entity52 ( pictured ) and author @entity54 the drug is given as an intravenous injection costing £ 600 a week , with an average course of treatment costing £ 5,000			1
trial data shows that @entity5 and chemotherapy increases average survival by two months , but also increases the number of patients alive after two years			2
professor @entity69 , professor of @entity70 in @entity71 , said ‘ this is very depressing news for patients with metastatic pancreatic cancer who already have very limited treatment options			1
‘ this negative @entity12 decision means that hundreds of patients with metastatic pancreatic cancer , who could potentially benefit from @entity5 , will not have access to it			1
‘ for a cancer which has such poor survival rates , this is a very sad decision by @entity12 and now leaves clinicians with limited treatment options			0
’ abraxane is currently available through the @entity85 ( @entity85 ) in @entity14 , but could be axed as part of a cost - cutting review			0
over 260 advanced pancreatic cancer patients have received it via the @entity85 since march			1
mother of five @entity91 , 54 , who lives near @entity92 with partner @entity93 , 50 , was diagnosed with pancreatic cancer at the end of august , after a short period of stomach symptoms			2
about 8,500 people in @entity41 are diagnosed annually with pancreatic cancer , which kills four in five sufferers within a year ( pictured is a cancer cell ) within a couple of weeks she was in excruciating pain and warned the cancer had spread to several sites in her body			2
she went on to @entity5 after her consultant at @entity110 applied for funding and has felt well since			0
ms @entity91 , who was a nurse specialising in learning disability patients , says the drug meant she could enjoy @entity114 with her family			0
‘ i ’d been as fit as a fiddle until this summer , i ’ve never had any call on the @entity2 until now and there is nothing else for someone like me			0
‘ it ’s too distressing to imagine others will have to go without ’ she added			0
@entity124 - based oncologist dr @entity123 said this is very disappointing news for both clinicians and patients			0
‘ a two month survival benefit in pancreatic cancer is actually extremely significant given the average survival for metastatic patients of 6 - 8 months			1
‘ if this negative review is upheld it would be a backwards step for pancreas cancer patients in @entity14			0
’ ms @entity136 , chief executive of @entity28 @entity41 charity , called on @entity12 to reconsider			0
she said ‘ the @entity12 decision and the review by the @entity85 which could lead to @entity5 being removed from the @entity85 , is devastating news for patients with metastatic pancreatic cancer who currently have very few treatment options			1
’ dr @entity144 , medical director , @entity146 @entity41 & @entity147 which makes the drug , said ‘ this decision is a serious setback for both clinicians and patients			0
’ sir @entity154 , @entity12 chief executive , said @entity5 was more effective than one of the treatment options currently available , but was also more expensive .			2

first drug for pancreatic cancer in 20 years wo *n't* be available on @entity2
hundreds of patients with advanced disease will be denied @entity5
drug extends life by two months when there are no other options left
but experts say the drug is not cost effective at £ 600 a week per patient
campaigners say they are ' outraged ' by the decision to not stock the drug

@entity26:Ali Stunt
@entity28:Pancreatic Cancer
@entity114:Christmas
@entity85:CDF
@entity110:Bedford Hospital
@entity136:Alex Ford
@entity154:Andrew Dillon
@entity2:NHS
@entity5:Abraxane
@entity92:Bedford
@entity53:Apple
@entity52:Steve Jobs
@entity57:Coronation Street
@entity56:Hayley Cropper
@entity54:Iain Banks
@entity71:Leicester
@entity70:Medical Oncology
@entity14:England
@entity12:NICE
@entity37:Europe
@entity124:London
@entity93:Roy
@entity123:Andrew Gaya
@entity91:Hukin
@entity144:Adrian Kilcoyne
@entity146:Celgene
@entity147:Ireland
@entity41:UK
@entity69:Will Steward